Blueprint Medicines Corporation (BPMC)
BPMC moved a median of -0.03% 30 minutes after news, and +0.09% by the close. How BPMC actually reacts to news — the realized, point-in-time move the market made, measured across 401 labeled events over the last three years with zero look-ahead.
BPMC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.02% | 50% | 351 |
| 30-min | -0.03% | 46% | 353 |
| 60-min | -0.06% | 45% | 353 |
| to close | +0.09% | 54% | 355 |
| Middle 50% of BPMC reactions | -0.57% to +0.49% |
|---|---|
| Median reaction (30-min) | -0.03% |
| Measured reactions | 401 |
Half of all Blueprint Medicines Corporation news events land between -0.57% and +0.49% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How BPMC reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 15 | -0.42% | 27% | -0.94% |
| Analyst downgrades | 27 | -0.09% | 26% | -0.16% |
| Coverage initiations | 20 | -1.34% | 20% | -2.37% |
| Rating reiterations | 102 | -0.09% | 43% | -0.52% |
| Price-target raises | 24 | -0.04% | 46% | -0.77% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how BPMC ranks against every other measured name →
That’s how BPMC usually reacts — get an email when it moves on news →Email me when BPMC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BPMC's baseline. Nothing else.
Recent BPMC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Blueprint Medicines Corp | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT Blueprint Medicines Corp | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 8-K Blueprint Medicines Corp For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM Blueprint Medicines Corp | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS Blueprint Medicines Corp | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 8-K Blueprint Medicines Corp For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | -0.14% | -0.07% | |
| Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses | Press release | PR Newswire | -0.13% | -0.17% | |
| BPMC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Blueprint Medicines Corporation Is Fair to Shareholders | Press release | Business Wire | -0.10% | -0.16% | |
| Form 8-K Blueprint Medicines Corp For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | -0.10% | -0.16% | |
| Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology | Press release | PR Newswire | -0.10% | -0.16% | |
| Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance | Press release | PR Newswire | +0.80% | +8.90% | |
| Form 10-Q Blueprint Medicines Corp For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.95% | +5.43% | |
| Form 8-K Blueprint Medicines Corp For: May 01 | SEC filing · Form 8-K | SEC EDGAR | +0.80% | +8.90% | |
| Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 | Press release | PR Newswire | -0.35% | +3.40% | |
| Form ARS Blueprint Medicines Corp For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.35% | +3.40% | |
| Form DEF 14A Blueprint Medicines Corp For: Jun 18 | SEC filing · Form DEF | SEC EDGAR | -0.35% | +3.40% | |
| Form DEFA14A Blueprint Medicines Corp | SEC filing · Form DEFA14A | SEC EDGAR | -0.35% | +3.40% | |
| Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference | Press release | PR Newswire | -0.37% | +1.95% | |
| Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress | Press release | PR Newswire | +0.28% | +6.72% | |
| Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results | Press release | PR Newswire | +0.76% | +0.20% | |
| Form 10-K Blueprint Medicines Corp For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.65% | -2.43% | |
| Form 8-K Blueprint Medicines Corp For: Feb 13 | SEC filing · Form 8-K | SEC EDGAR | +0.76% | +0.20% | |
| Form S-8 Blueprint Medicines Corp | SEC filing · Form S-8 | SEC EDGAR | -0.65% | -2.43% | |
| Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025 | Press release | PR Newswire | +0.04% | -2.80% | |
| Form 8-K Blueprint Medicines Corp For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | -0.64% | +7.18% | |
| Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth | Press release | PR Newswire | +4.91% | +14.55% | |
| Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference | Press release | PR Newswire | -1.33% | -5.43% | |
| Form 8-K Blueprint Medicines Corp For: Dec 13 | SEC filing · Form 8-K | SEC EDGAR | -0.70% | -3.17% | |
| Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting | Press release | PR Newswire | +0.74% | -1.79% | |
| Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance | Press release | PR Newswire | +1.52% | -3.00% | |
| Form 10-Q Blueprint Medicines Corp For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.60% | -1.93% | |
| Form 8-K Blueprint Medicines Corp For: Oct 30 | SEC filing · Form 8-K | SEC EDGAR | +1.52% | -3.00% | |
| Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 | Press release | PR Newswire | +0.00% | -0.82% | |
| Blueprint Medicines to Present at Upcoming Investor Conferences | Press release | PR Newswire | +0.08% | -1.07% | |
| Investors Are Urged To Participate In An Investigation Into Blueprint Medicines Corporation's Potential Securities Law Violations | Press release | Accesswire | -0.03% | +0.03% | |
| Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance | Press release | PR Newswire | +0.27% | -5.84% | |
| Form 10-Q Blueprint Medicines Corp For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.21% | +0.35% | |
| Form 8-K Blueprint Medicines Corp For: Aug 01 | SEC filing · Form 8-K | SEC EDGAR | +0.27% | -5.84% | |
| Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 | Press release | PR Newswire | -0.70% | -0.01% | |
| Form S-8 Blueprint Medicines Corp | SEC filing · Form S-8 | SEC EDGAR | -1.01% | +1.73% | |
| Form 8-K Blueprint Medicines Corp For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | -0.32% | -1.11% | |
| Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib) | Press release | PR Newswire | +0.13% | -2.10% | |
| Form 8-K Blueprint Medicines Corp For: May 22 | SEC filing · Form 8-K | SEC EDGAR | +0.71% | +0.06% | |
| Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting | Press release | PR Newswire | +0.71% | +0.06% | |
| Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | -0.37% | +2.42% | |
| Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance | Press release | PR Newswire | -0.88% | +3.00% | |
| Form 10-Q Blueprint Medicines Corp For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.97% | -2.40% | |
| Form 8-K Blueprint Medicines Corp For: May 02 | SEC filing · Form 8-K | SEC EDGAR | -0.88% | +3.00% | |
| Form 8-K Blueprint Medicines Corp For: Apr 25 | SEC filing · Form 8-K | SEC EDGAR | -0.27% | +1.33% | |
| Form ARS Blueprint Medicines Corp For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.25% | +0.26% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BPMC section they belong to.
Where else BPMC is measured.
BPMC earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| SPRING BANK PHARMACEUTICALS (SBPH) | 404 | 0.00% | 37% |
| AKCEA THERAPEUTICS (AKCA) | 401 | 0.00% | 49% |
| EDGE THERAPEUTICS (EDGE) | 401 | -0.05% | 41% |
| Esperion Therapeutics, Inc. (ESPR) | 401 | 0.00% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Blueprint Medicines Corporation's median reaction calculated?
Every labeled BPMC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 401 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of BPMC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BPMC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.